{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Boers M"],"funding":["European Commission"],"pagination":["925-936"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9209692"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["81(7)"],"pubmed_abstract":["Background
Low-dose glucocorticoid (GC) therapy is widely used in rheumatoid arthritis (RA) but the balance of benefit and harm is still unclear.Methods
The GLORIA (Glucocorticoid LOw-dose in RheumatoId Arthritis) pragmatic double-blind randomised trial compared 2 years of prednisolone, 5 mg/day, to placebo in patients aged 65+ with active RA. We allowed all cotreatments except long-term open label GC and minimised exclusion criteria, tailored to seniors. Benefit outcomes included disease activity (disease activity score; DAS28, coprimary) and joint damage (Sharp/van der Heijde, secondary). The other coprimary outcome was harm, expressed as the proportion of patients with ≥1 adverse event (AE) of special interest. Such events comprised serious events, GC-specific events and"],"journal":["Annals of the rheumatic diseases"],"pubmed_title":["Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial."],"pmcid":["PMC9209692"],"funding_grant_id":["Horizon 2020: 634886"],"pubmed_authors":["Allaart CF","Pinto R","Celano A","Richards P","Buttgereit F","Costa J","Raterman HG","Corduta P","Manger S","Klausch LT","Bos R","Ruiterman Y","Cutolo M","Middelink LM","Molenaar E","van Laar JM","Frazao Mateus E","Boonen A","Klaasen R","Marsman AF","Doerwald L","Codreanu C","Sieburg M","van der Heijde D","Griep EN","Masaryk P","Dekker V","Constantinescu O","GLORIA Trial consortium","Silva I","Spoorenberg J","Jacobs J","Smulders YM","Kok MR","Mendes G","Baudoin P","van den Bulk N","Elling-Audersch C","Micaelo M","Schilder AM","Aanerud GJ","Christensen R","Boers M","Szekanecz Z","Bijlsma J","Nurmohamed MT","Tas SW","Paolino S","Opris-Belinski D","Borucki D","Rusthoven C","Prinsen K","Scholte-Voshaar M","Saavedra MJ","Redol J","Jansen T","Lems WF","Ralston SH","Bakkers M","Prothmann U","Hartman L","Da Silva JA"],"additional_accession":[]},"is_claimable":false,"name":"Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial.","description":"Background
Low-dose glucocorticoid (GC) therapy is widely used in rheumatoid arthritis (RA) but the balance of benefit and harm is still unclear.Methods
The GLORIA (Glucocorticoid LOw-dose in RheumatoId Arthritis) pragmatic double-blind randomised trial compared 2 years of prednisolone, 5 mg/day, to placebo in patients aged 65+ with active RA. We allowed all cotreatments except long-term open label GC and minimised exclusion criteria, tailored to seniors. Benefit outcomes included disease activity (disease activity score; DAS28, coprimary) and joint damage (Sharp/van der Heijde, secondary). The other coprimary outcome was harm, expressed as the proportion of patients with ≥1 adverse event (AE) of special interest. Such events comprised serious events, GC-specific events and","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jul","modification":"2026-06-08T06:49:44.106Z","creation":"2026-06-08T03:14:11.416Z"},"accession":"S-EPMC9209692","cross_references":{"pubmed":["35641125"],"doi":["10.1136/annrheumdis-2021-221957"]}}